Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EBT (2016 - 2025)

Macrogenics (MGNX) has disclosed EBT for 14 consecutive years, with -$14.9 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 3.14% to -$14.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$78.4 million, a 10.66% decrease, with the full-year FY2025 number at -$75.3 million, down 14.04% from a year prior.
  • EBT was -$14.9 million for Q4 2025 at Macrogenics, down from $16.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $54.2 million in Q3 2024 to a low of -$66.6 million in Q1 2022.
  • A 5-year average of -$32.2 million and a median of -$41.0 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: crashed 2583.69% in 2021, then soared 252.64% in 2024.
  • Macrogenics' EBT stood at -$58.2 million in 2021, then skyrocketed by 120.58% to $12.0 million in 2022, then tumbled by 511.87% to -$49.4 million in 2023, then surged by 70.67% to -$14.5 million in 2024, then dropped by 3.14% to -$14.9 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's EBT are -$14.9 million (Q4 2025), $16.8 million (Q3 2025), and -$37.6 million (Q2 2025).